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Abstract 
Purpose: To investigate the epidermal growth factor receptor (EGFR) gene mutations and analyze their 
clinical significance in patients with non-small cell lung cancer (NSCLC) in Hubei province of China.  
Methods: A total of 138 paraffin embedded tissues were taken from patients with NSCLC who were 
treated at Hubei Hospital from January 2014 to June 2015. The tissue DNA was extracted and EGFR 
mutation was evaluated by polymerase chain reaction (PCR) sequencing analysis of exons 18, 19, 20, 
and 21. 
Results: The overall mutation rate of EGFR gene was 30.43 % (42/138) in 138 NSCLC patients. The 
mutation rates of EGFR gene at exon 18, 19, 20, 21 were 0 %（0/138), 13.8 %（19/138), 0.7 % (1/138) 
and 15.9 % (22/138), respectively. The mutation rate of EGFR gene was higher in female patients than 
that in males (62.2 % (28/45) vs 15.1 % (14/93), p < 0.01), and higher in non-smoking patients than in 
smoking ones (p < 0.05), but had no correlation with age in NSCLC patients (p > 0.05). EGFR mutation 
frequency in adenocarcinoma was higher than that in squamous cell carcinoma: 33.9 % (41/121) vs. 5.9 
% (1/17, p < 0.05). 
Conclusion: EGFR mutations in NSCLC patients mainly exist in exons 19 and 21, and the mutation 
rate of exon 21 is higher than that of exon 19, which is more commonly found in female, 
adenocarcinoma and non-smoking patients. 
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Lung cancer is one of the most common cancers 
in the world and is responsible for one third of all 
cancer-related death [1], NSCLC comprising 80 
% of lung cancers is now a disease that can be 
classified into clinically relevant molecular 
subgroups, each with distinct clinicopathologic 
features and potential for targeted therapies [2]. 
Among these molecular subsets, the 
identification of EGFR tyrosine kinase domain 
mutations that predict sensitivity to tyrosine 
kinase inhibitors (TKIs) is the most prominent 
event [3-5]. Patients with EGFR mutations, 
however, are also a heterogeneous group with 
different sensitivity to TKIs, such as erlotinib or 
gefitinib. EGFR kinase domain mutations occur 
primarily in exons 18-21 which encode part of the 
tyrosine kinase domain [6-8]. 
 
The presence of EGFR mutations has also been 
associated with treatment in East Asian 
countries, female sex, bronchioloalveolar 
carcinoma subtype of adenocarcinoma, and 
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improved survival [9]. One factor with a very 
strong association with these sensitivity 
mutations was a history of never smoking 
cigarettes [10]. Patients with a high likelihood of 
response to treatment with tyrosine kinase 
inhibitors can be identified by molecular analysis 
of lung tumor tissue to detect these sensitivity 
mutations. The personalization of cancer care 
aims to predict effective therapy regimes 
according to the molecular profiles of individual 
patients and their cancers and only patients who 
carried EGFR mutation can benefit from targeted 
therapies [4,11].  
 
In this study, we performed multiplex 
amplification of exons 18-21 of EGFR using 
pyrosequencing to detect base changes or 
deletions in codons 746-753 to analyze the 
mutational frequency in 138 cases of lung cancer 
and provide theoretical basis for individualized 
diagnosis and treatment of lung cancer patients 






Tumor specimens were collected from 138 
patients with NSCLC at the time of surgical 
resection before systemic treatment. All 
specimens were frozen immediately and stored 
in liquid nitrogen until DNA was extracted. 
Demographic characteristics and clinical data, 
including age, sex, smoking status, date of 
diagnosis, tumor stage, treatment, progression 
were obtained. Our institutional review board 
approved this study, and written informed 
consent was obtained from all patients. This 
study was approved by the Ethics Committee of 
the Hubei Hospital (approval ref. no. 20140101) 
and followed the guidelines of Helsinki 
Declaration [12].  
 
DNA extraction, PCR and direct sequencing 
of EGFR gene 
 
DNA of the tumor tissue was successfully  
extracted by TIANamp Blood/cell/tissue genomic 
DNA extraction kit (Tiangen, Beijing, China) 
according to the manufacturer’s instruction. Four 
separate PCR reactions, each with the 
corresponding pair of primers, were used to 
amplify exons 18-21 of the EGFR genes. The 
designed primers were as follows. Exon 18: 
Forward: 5’-CAA GTG CCG TGT CCT GG-3’; 
Reverse: 5’-AAA TGC CTT TGG TCT GTG AA-
3’, Exon 19: Forward: 5’-ATA TCA GCC TTA 
GGT GCG G-3’, Reverse: 5’-GGG AAA GAC 
ATA GAA AGT GAA CA-3’, Exon 20: Forward: 
5’-TTC ACA GCC CTG CGT AAA C-3’, Reverse: 
5’-TTG AAT CCA AAA TAA AGG AAT GT-3’; 
Exon 21: Forward: 5’-TGG TCA GCA GCG GGT 
TAC-3’, Reverse: 5’-TCA TTC ACT GTC CCA 
GCA AG-3’. PCR amplification was carried out 
on ABI 9700 PCR thermal cycler (Applied 
Biosystems, USA). The PCR amplification was 
performed with a denaturation step at 94 °C for 2 
min, followed by 35 cycles of 94 °C for 20 s, 52 
°C for 10 s, 72 °C for 30 s, and final extension 
step at 72 °C for 2 min. The PCR products were 
analyzed using a PyroMark Q24 system (Qiagen) 
according to standard protocols. The order of 
nucleotide dispensation was chosen based on 
suggestions provided by the PyroMark Assay 




The association between two categorical 
variables was assessed using the Chi-square 
test. Allele frequency was determined via direct 
counting and a p-value less than 0.05 denoted 







There were 93 men and 45 women. Sixty six 
patients declared their smoking history. The 
clinical and demographic characteristics of the 
138 NSCLC patients are shown in Table 1. 
 
 
Table 1: The clinical and demographic characteristics of NSCLC patients 
 
Variable General data  Cases (N) Percentage (% ) 
Gender Male  93 67.4 (93/138) Female  45 32.6 (45/138) 
Age ≤ 60 years  103 74.6 (103/138) > 60 years  35 25.4 (35/138) 
Smoking or not 
Smoking Male 61 44.2 (61/138) Female 5 3.6 (5/138) 
Non-Smoking Male 32 23.2 (32/138) Female 40 29.0 (40/138) 
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Distribution of EGFR mutations in 138 NSCLC 
patients 
 
The overall mutation rate in EGFR was 30.43 % 
(42/138). With respect to the EGFR mutation 
status, we found 19 patients (13.8 %) with an in-
frame deletion in exon 19, 21 patients (15.2 %) 
with L858R mutations and 1 patient (0.7 %) with 
L861Q mutation in exon 21 and 1 patient (0.7 %) 
with T790M mutation in exon 20 in the 138 
NSCLC patients, as shown in Table 2. 
 
Association between EGFR mutation and 
clinical characteristics in 138 NSCLC patients  
 
As shown in Table 3, the mutation rate of EGFR 
gene had no correlation with age in NSCLC 
patients (30.1 % vs 31.4 %, p > 0.05), it was 
higher in female patients than that in males (62.2 
% (28/45) vs 15.1% (14/93), p < 0.01), and 
higher in non-smoking patients than in smoking 
ones (28.1 % vs 8.2 % in males, 71.8 % vs 16.7 
% in females, p < 0.05). EGFR mutation 
frequency in adenocarcinoma was higher than 
that in squamous cell carcinoma (33.9 % vs 5.9 
%, p < 0.05). 
 
As shown in Table 4, in both adenocarcinoma 
and squamous cell carcinoma, the mutation rate 
of EGFR gene was higher in female patients than 




Gefitinib and erlotinib are orally available EGFR-
TKIs frequently used to treat NSCLC patients 
with EGFR mutations [13,14]. EGFR proteins 
control essential signaling pathways that regulate 
cell proliferation [15]. Increased levels of EGFR 
gene expression are observed in NSCLC, and its 
expression is correlated with an adverse 
prognosis [16]. 
 
Table 2: Mutations status in exons 18 - 21 of EGFR in 138 NSCLC patients 
 
Exon Mutations type Mutation cases Mutation rate (%) 
18 G719S 0 0 (0/41) 
19 Del E746-A750  19 13.8 (19/41) 
20 T790M 1 0.7 (1/41) 
21 L861Q 1 0.7 (1/41) L858R 21 15.2 (21/41) 
Total  42 30.43 (42/138) 
 
Table 3: Association between EGFR mutation and clinical characteristics in 138 NSCLC patients 
 
Clinical characteristics Detected cases 
EGFR Mutation rate 
(%) P-value Mutation No mutation 
Age      
   ≤ 60 years 103 31 72 30.1 0.882    > 60 years 35 11 24 31.4 
Gender      
   Male 93 14 79 15.1 0.000    Female 45 28 17 62.2 
Smoking or not      
Male  Smoking 61 5 56 8.2 0.011  No smoking 32 9 23 28.1 
Female  Smoking 6 1 5 16.7 0.030  No smoking 39 28 11 71.8 
Histological type      
Adenocarcinoma 121 41 80 33.9 0.039 squamous cell carcinoma 17 1 16 5.9 
 




(n=121) Mutation rate 
(%) 
Squamous cell carcinoma 




type  Mutant-type Wild-type  
Male 13 70 15.7 0 10 0 
Female 25 13 65.8 1 6 14.3 
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EGFR mutations have been found more 
frequently in non-smoking East Asian women 
with adenocarcinoma with NSCLC [17,18]. 
 
The ethnic and region differences in the 
incidence of EGFR mutations in NSCLC remain 
incompletely understood. In this study, we chose 
a population of Hubei patients to study the 
incidence rate of EGFR mutations. The overall 
mutation rate of EGFR gene was 30.43 % in 
Hubei NSCLC patients, consistent with data 
reported for other East Asian populations [19]. 
The mutation rates of EGFR gene at exon 18, 
19, 20, 21 were 0, 13.8, 0.7 and 15.9 %, 
respectively. The mutation rate of EGFR gene 
was higher in female patients than that in males 
(p < 0.01), and higher in non-smoking patients 
than in smoking ones, this finding suggests that 
endogenous agents from female hormone-
derived mutagenic metabolites may play a role in 
EGFR mutagenesis. 
 
Furthermore, it has been shown that females are 
more susceptible to environmental carcinogens 
because DNA mutations were more frequently 
found in never-smoking female than never-
smoking male lung cancer patients [20]. But the 
mutation rate of EGFR gene had no correlation 
with age in NSCLC patients (p > 0.05); EGFR 
mutation frequency in adenocarcinoma was 
higher than that in squamous cell carcinoma (p < 
0.05), and the mutation rate of EGFR gene was 
also higher in female patients than that in males. 
 
In our analysis, the frequency of EGFR mutations 
in patients who had never-smoking was 48.6 % 
(35 of 72 patients). The frequency of EGFR 
mutations has been observed to vary from 26 % 
to 68 % based on how the mutational analysis 
was performed, geography and other clinical 
characteristics of the patients investigated [21-
23]. Shigematsu and Pham identified EGFR 
mutations in 51 % of those who have never 
smoked (85 of 166, 34 of 67 patients), and so the 
results similar to ours [19,24]. 
 
Clinical parameters and molecular characteristics 
are very useful to the therapy for lung cancer. 
The study demonstrate that a universally 
available and verifiable clinical characteristic can 
estimate the incidence of mutations in exons 18, 
19, 20 and 21 of EGFR, and assist physicians in 
choosing appropriate therapy for each individual 
patient. 
 
Limitation of the study 
 
In this study, the sample size of participants was 
small; thus, the results may be biased. 





EGFR mutations in NSCLC patients are mainly 
found in exons 19 and 21, and the mutation rate 
of exon 21 is higher than that of exon 19, which 
is the one more commonly found in female, 
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